Search

Jeffrey S. Parkin

Examiner (ID: 2776)

Most Active Art Unit
1648
Art Unit(s)
1648, 1641, 1813, 1671
Total Applications
1731
Issued Applications
935
Pending Applications
260
Abandoned Applications
571

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 9482542 [patent_doc_number] => 08728488 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-20 [patent_title] => 'Methods of inducing an immune response in a host by administering flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens' [patent_app_type] => utility [patent_app_number] => 13/338529 [patent_app_country] => US [patent_app_date] => 2011-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12037 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13338529 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/338529
Methods of inducing an immune response in a host by administering flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens Dec 27, 2011 Issued
Array ( [id] => 9901046 [patent_doc_number] => 20150056247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-26 [patent_title] => 'Sequential and repeated immunization with four or more vector-based HIV gene vaccines' [patent_app_type] => utility [patent_app_number] => 14/233191 [patent_app_country] => US [patent_app_date] => 2011-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3187 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14233191 [rel_patent_id] =>[rel_patent_doc_number] =>)
14/233191
Sequential and repeated immunization with four or more vector-based HIV gene vaccines Dec 22, 2011 Abandoned
Array ( [id] => 8138611 [patent_doc_number] => 20120093858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-19 [patent_title] => 'Tat-Based Tolerogen Compositions and Methods for Making and Using Same' [patent_app_type] => utility [patent_app_number] => 13/336294 [patent_app_country] => US [patent_app_date] => 2011-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 11509 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0093/20120093858.pdf [firstpage_image] =>[orig_patent_app_number] => 13336294 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/336294
Tat-Based Tolerogen Compositions and Methods for Making and Using Same Dec 22, 2011 Abandoned
Array ( [id] => 11908238 [patent_doc_number] => 09777042 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-03 [patent_title] => 'Method of purifying HIV/SIV Nef from exosomal fusion proteins' [patent_app_type] => utility [patent_app_number] => 13/327244 [patent_app_country] => US [patent_app_date] => 2011-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 14944 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13327244 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/327244
Method of purifying HIV/SIV Nef from exosomal fusion proteins Dec 14, 2011 Issued
Array ( [id] => 11767911 [patent_doc_number] => 09376486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-28 [patent_title] => 'Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/993983 [patent_app_country] => US [patent_app_date] => 2011-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 25 [patent_no_of_words] => 17525 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13993983 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/993983
Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof Dec 13, 2011 Issued
Array ( [id] => 8536842 [patent_doc_number] => RE043823 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2012-11-20 [patent_title] => 'Human monoclonal antibody against coreceptors for human immunodeficiency virus' [patent_app_type] => reissue [patent_app_number] => 13/300340 [patent_app_country] => US [patent_app_date] => 2011-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 23 [patent_no_of_words] => 26292 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13300340 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/300340
Human monoclonal antibody against coreceptors for human immunodeficiency virus Nov 17, 2011 Abandoned
Array ( [id] => 9147841 [patent_doc_number] => 20130302364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'HIGHLY IMMUNOGENIC HIV P24 SEQUENCES' [patent_app_type] => utility [patent_app_number] => 13/884634 [patent_app_country] => US [patent_app_date] => 2011-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 15396 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884634 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/884634
HIGHLY IMMUNOGENIC HIV P24 SEQUENCES Nov 9, 2011 Abandoned
Array ( [id] => 9435029 [patent_doc_number] => 20140112936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-24 [patent_title] => 'METHODS OF NEUTRALIZING VIRAL INFECTION' [patent_app_type] => utility [patent_app_number] => 13/884823 [patent_app_country] => US [patent_app_date] => 2011-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 20020 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884823 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/884823
Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41 Nov 8, 2011 Issued
Array ( [id] => 10629803 [patent_doc_number] => 09347951 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region' [patent_app_type] => utility [patent_app_number] => 13/882041 [patent_app_country] => US [patent_app_date] => 2011-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 14911 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13882041 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/882041
Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region Oct 27, 2011 Issued
Array ( [id] => 10168271 [patent_doc_number] => 09198964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-01 [patent_title] => 'Recombinant subunit dengue virus vaccine' [patent_app_type] => utility [patent_app_number] => 13/881423 [patent_app_country] => US [patent_app_date] => 2011-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 16647 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13881423 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/881423
Recombinant subunit dengue virus vaccine Oct 26, 2011 Issued
Array ( [id] => 7776315 [patent_doc_number] => 20120039894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-16 [patent_title] => 'IDENTIFICATION OF THERAPEUTIC AGENTS FOR HIV INFECTION' [patent_app_type] => utility [patent_app_number] => 13/280070 [patent_app_country] => US [patent_app_date] => 2011-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 15297 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0039/20120039894.pdf [firstpage_image] =>[orig_patent_app_number] => 13280070 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/280070
Method for inhibiting dendritic cell immunoreceptor (DCIR)-mediated human immunodeficiency virus infection comprising administering anti-DCIR antibodies Oct 23, 2011 Issued
Array ( [id] => 8172398 [patent_doc_number] => 20120107910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-03 [patent_title] => 'RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/279250 [patent_app_country] => US [patent_app_date] => 2011-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5718 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0107/20120107910.pdf [firstpage_image] =>[orig_patent_app_number] => 13279250 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/279250
Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41 Oct 21, 2011 Issued
Array ( [id] => 8301041 [patent_doc_number] => 20120183597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-19 [patent_title] => 'Method of inducing neutralizing antibodies to human immunodeficiency virus' [patent_app_type] => utility [patent_app_number] => 13/200865 [patent_app_country] => US [patent_app_date] => 2011-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 7655 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13200865 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/200865
Method of inducing neutralizing antibodies to human immunodeficiency virus Oct 3, 2011 Abandoned
Array ( [id] => 8989721 [patent_doc_number] => 20130217002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'HIV-1 IGG3 RESPONSE IN ACUTE HIV-1' [patent_app_type] => utility [patent_app_number] => 13/877281 [patent_app_country] => US [patent_app_date] => 2011-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8732 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13877281 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/877281
HIV-1 IGG3 RESPONSE IN ACUTE HIV-1 Oct 2, 2011 Abandoned
Array ( [id] => 11357377 [patent_doc_number] => 09534020 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-03 [patent_title] => 'Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide' [patent_app_type] => utility [patent_app_number] => 13/876918 [patent_app_country] => US [patent_app_date] => 2011-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13798 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13876918 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/876918
Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide Sep 27, 2011 Issued
Array ( [id] => 9227117 [patent_doc_number] => 08632782 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-21 [patent_title] => 'Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region' [patent_app_type] => utility [patent_app_number] => 13/240849 [patent_app_country] => US [patent_app_date] => 2011-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 53296 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13240849 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/240849
Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region Sep 21, 2011 Issued
Array ( [id] => 7669108 [patent_doc_number] => 20110318377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-29 [patent_title] => 'Methylated TAT Polypeptides and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 13/230540 [patent_app_country] => US [patent_app_date] => 2011-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 25073 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13230540 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/230540
Screening method for the identification of inhibitors of HIV Tat methylation by the lysine methyltransferase Set7/9 Sep 11, 2011 Issued
Array ( [id] => 8232648 [patent_doc_number] => 08198088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-06-12 [patent_title] => 'Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)' [patent_app_type] => utility [patent_app_number] => 13/221952 [patent_app_country] => US [patent_app_date] => 2011-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 19213 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/198/08198088.pdf [firstpage_image] =>[orig_patent_app_number] => 13221952 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/221952
Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs) Aug 30, 2011 Issued
Array ( [id] => 8532945 [patent_doc_number] => 08309098 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-11-13 [patent_title] => 'Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs)' [patent_app_type] => utility [patent_app_number] => 13/222020 [patent_app_country] => US [patent_app_date] => 2011-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 19213 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13222020 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/222020
Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs) Aug 30, 2011 Issued
Array ( [id] => 7732480 [patent_doc_number] => 20120015423 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-19 [patent_title] => 'INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA' [patent_app_type] => utility [patent_app_number] => 13/221108 [patent_app_country] => US [patent_app_date] => 2011-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 19123 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0015/20120015423.pdf [firstpage_image] =>[orig_patent_app_number] => 13221108 [rel_patent_id] =>[rel_patent_doc_number] =>)
13/221108
Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) Aug 29, 2011 Issued
Menu